SCHEMBL3583033

SCHEMBL3583033

C[C@@H]1CN(c2ccc(OCCCN3CCCCC3)cc2)[C@H](C)CN1C(=O)N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 18/20 0.52
HRH2 P25021 2/20 0.48
HRH1 P35367 2/20 0.48
KCNH2 Q12809 3/20 0.48
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47
CHRM2 P08172 2/20 0.46
CHRM1 P11229 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
HTR2A P28223 1/20 0.46
MAPK1 P28482 1/20 0.46
SCN1A P35498 1/20 0.46
HTR2B P41595 1/20 0.46
SCN2A Q99250 1/20 0.46
SIGMAR1 Q99720 1/20 0.46
SCN3A Q9NY46 1/20 0.46
ADRA2C P18825 1/20 0.46
CHRM3 P20309 1/20 0.46
DRD4 P21917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13438264 1.00 HRH3 (0.52) HRH3HRH2HRH1KCNH2POLB
SCHEMBL3586381 0.80 HRH3 (0.66) HRH3HRH2HRH1KCNH2POLB
SCHEMBL3583931 0.78 HRH3 (0.58) HRH3HRH2HRH1KCNH2SLC6A4
SCHEMBL3587285 0.77 POLB (0.56) HRH3HRH1KCNH2POLBMAPT
SCHEMBL4670410 0.75 HRH3 (0.73) HRH3KCNH2
Morpholine SCHEMBL6474550 0.75 HRH3 (0.58) HRH3HRH2HRH1KCNH2POLB
SCHEMBL3578990 0.71 HRH3 (0.55) HRH3HRH1KCNH2HRH4
SCHEMBL4675518 0.71 HRH3 (0.57) HRH3HRH2HRH1KCNH2
SCHEMBL3587160 0.70 HRH3 (0.65) HRH3HRH2HRH1KCNH2
SCHEMBL9809336 0.69 HRH1 (0.66) HRH3HRH2HRH1KCNH2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100075953-A1 SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
EP-1567511-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
WO-2004035556-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075953-A1 SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS HRH3, HRH4, HRH2 HRH3 1/4885HRH2 3/4885HRH1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.